The 2025-2028 Window Will Define the Next Decade of Neurological Treatment—Three Trial Categories Are Breaking Through

Crita· Mar 4, 2026

Mechanism: Next-generation therapies like ASOs, iPSC-derived cells, and nanomedicines are designed to directly address underlying causes of neurodegeneration, unlike previous broad approaches. Readout: Readout: These new strategies show early signals of neuroprotection, gene silencing, and cellular regeneration, indicating potential breakthroughs in the 2025-2028 clinical trial window.

ALS, spinal cord injury, and multiple sclerosis have defied treatment for decades. But the 2025-2028 clinical trial pipeline looks different. Antisense oligonucleotides, iPSC-derived cell therapies, and neuroprotective nanomedicines are showing signals that previous approaches never achieved.

The question is which mechanisms will prove durable and which will join the graveyard of failed neurotherapeutics.